By Colin Kellaher

 

Fennec Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration has accepted for filing its resubmitted application seeking approval of Pedmark for the prevention of hearing loss associated with cisplatin chemotherapy in children.

The Durham, N.C., specialty pharmaceutical company said the agency set a target action date of Sept. 23 for the application.

The FDA in November rejected Fennec's application for Pedmark, the company's lead drug candidate, for a second time due to issues at the plant where the drug is made.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

April 27, 2022 06:46 ET (10:46 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Fennec Pharmaceuticals (TSX:FRX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Fennec Pharmaceuticals
Fennec Pharmaceuticals (TSX:FRX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Fennec Pharmaceuticals